IDT Australia (ASX:IDT) share price rockets 40% on COVID vaccine update

What did IDT Australia update the ASX with?

| More on:
A drawing of a white rocket streaking up, indicating a surging share pirce movement

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is entering the stratosphere today. This comes after the pharmaceutical manufacturing company announced a significant market update in regards to Australia's mRNA manufacturing capability.

At the time of writing, IDT Australia shares are up 40.23% to 61 cents. This means that its shares have now more than tripled since the start of the year.

IDT Australia marks milestone achievement 

Investors appear excited about the company's latest COVID-19 update, rallying up the IDT Australia share price.

According to its release, the company advised it has successfully created Australia's first mRNA COVID-19 vaccine candidate.

The drug product passed all the required specifications and is now going through the release process for clinical trials. In total, 450 doses of the vaccine have been manufactured, allowing 150 volunteers to take part in the upcoming study. This is expected to commence in the new year, with results expected later in 2022.

Last month, IDT Australia entered into a Master Services Agreement and Services Order with Monash Institute of Pharmaceutical Sciences (MIPS). Following completion of the successful manufacture, IDT Australia will begin testing ongoing product stability.

A collaboration between MIPS, Doherty Institute and IDT Australia has put Victoria's medical research and manufacturing sectors in the spotlight. The state is one of the few places in the world with the capability to develop and manufacture mRNA therapeutics.

IDT Australia CEO, Dr David Sparling commented:

We're honoured to be a part of this collaboration. We believe this product will be the first locally developed mRNA COVID-19 vaccine candidate and the first locally manufactured cGMP mRNA drug product.

About the IDT Australia share price

Over the past 12 months, IDT Australia shares have gained around 215%. Year-to-date has surged even further, with the company share price up 225%.

IDT Australia presides a market capitalisation of roughly $143.92 million and has approximately 239.86 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A red heart-shaped balloon floats up above the plain white ones, indicating the best shares.
Healthcare Shares

Heart tech firm's shares surge after huge capital raise

A strategic investor has also jumped on board.

Read more »

Lab technician in lab with a tray of specimens
Healthcare Shares

Has this ASX 200 stock just turned the corner after 7% surge?

Brokers think the volatile biotech share can sustain the rally this time.

Read more »

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »